Citius Pharmaceuticals Stock Shares Outstanding
| CTXR Stock | USD 3.32 0.28 7.78% |
Citius Pharmaceuticals fundamentals help investors to digest information that contributes to Citius Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Citius Stock. The fundamental analysis module provides a way to measure Citius Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Citius Pharmaceuticals stock.
As of 11/29/2024, Common Stock Shares Outstanding is likely to grow to about 182.7 M. Citius | Shares Outstanding |
Citius Pharmaceuticals Company Shares Outstanding Analysis
Citius Pharmaceuticals' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Citius Pharmaceuticals Shares Outstanding | 180.72 M |
Most of Citius Pharmaceuticals' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Citius Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Citius Shares Outstanding Driver Correlations
Understanding the fundamental principles of building solid financial models for Citius Pharmaceuticals is extremely important. It helps to project a fair market value of Citius Stock properly, considering its historical fundamentals such as Shares Outstanding. Since Citius Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Citius Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Citius Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Citius Shares Outstanding Historical Pattern
Today, most investors in Citius Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Citius Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Citius Pharmaceuticals shares outstanding as a starting point in their analysis.
Citius Pharmaceuticals Shares Outstanding |
| Timeline |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Citius Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, Citius Pharmaceuticals has 180.72 M of shares currently outstending. This indicator is about the same for the Pharmaceuticals average (which is currently at 180.53 M) sector and 69.13% higher than that of the Health Care industry. The shares outstanding for all United States stocks is 68.39% higher than that of the company.
Citius Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Citius Pharmaceuticals' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Citius Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Citius Pharmaceuticals by comparing valuation metrics of similar companies.Citius Pharmaceuticals is currently under evaluation in shares outstanding category among its peers.
Citius Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Citius Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Citius Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Citius Fundamentals
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.25 | ||||
| Current Valuation | 10.23 M | ||||
| Shares Outstanding | 180.72 M | ||||
| Shares Owned By Insiders | 6.80 % | ||||
| Shares Owned By Institutions | 17.02 % | ||||
| Number Of Shares Shorted | 13.45 M | ||||
| Price To Earning | (1.34) X | ||||
| Price To Book | 0.32 X | ||||
| EBITDA | (36.73 M) | ||||
| Net Income | (32.54 M) | ||||
| Cash And Equivalents | 48.04 M | ||||
| Cash Per Share | 0.33 X | ||||
| Total Debt | 481.25 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 11.40 X | ||||
| Book Value Per Share | 0.47 X | ||||
| Cash Flow From Operations | (29.06 M) | ||||
| Short Ratio | 13.22 X | ||||
| Earnings Per Share | (0.24) X | ||||
| Target Price | 4.67 | ||||
| Number Of Employees | 22 | ||||
| Beta | 1.66 | ||||
| Market Capitalization | 87.15 M | ||||
| Total Asset | 103.61 M | ||||
| Retained Earnings | (162.23 M) | ||||
| Working Capital | 28.59 M | ||||
| Current Asset | 893 K | ||||
| Current Liabilities | 5.18 M | ||||
| Net Asset | 103.61 M |
About Citius Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Citius Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Citius Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Citius Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Citius Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Citius Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Citius Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Citius Stock
| 0.71 | HLN | Haleon plc | PairCorr |
| 0.71 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.74 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.68 | ANRO | Alto Neuroscience, | PairCorr |
Moving against Citius Stock
| 0.82 | AXP | American Express Fiscal Year End 24th of January 2025 | PairCorr |
| 0.75 | TRV | The Travelers Companies Fiscal Year End 17th of January 2025 | PairCorr |
| 0.69 | FNMFO | Federal National Mortgage Upward Rally | PairCorr |
| 0.67 | KB | KB Financial Group | PairCorr |
| 0.62 | ITCL | Banco Ita Chile | PairCorr |
The ability to find closely correlated positions to Citius Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Citius Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Citius Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Citius Pharmaceuticals to buy it.
The correlation of Citius Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Citius Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Citius Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Citius Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Citius Stock Analysis
When running Citius Pharmaceuticals' price analysis, check to measure Citius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Pharmaceuticals is operating at the current time. Most of Citius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Citius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Citius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.